<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Middle East J Dig Dis</journal-id><journal-id journal-id-type="iso-abbrev">Middle East J Dig Dis</journal-id><journal-id journal-id-type="publisher-id">Middle East J Dig Dis</journal-id><journal-id journal-id-type="publisher-id">MEJDD</journal-id><journal-title-group><journal-title>Middle East Journal of Digestive Diseases</journal-title></journal-title-group><issn pub-type="ppub">2008-5230</issn><issn pub-type="epub">2008-5249</issn><issn-l>2008-5230</issn-l><publisher><publisher-name>Iranian Association of Gastroerterology and Hepatology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24829699</article-id><article-id pub-id-type="pmc">4005479</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of Adding Metformin to Pegylated Interferon and Ribavirin in Treatment Na&#x000ef;ve Patients with Chronic Hepatitis C: A Randomized Double-Blind Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sharifi</surname><given-names>Amir Houshang</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mohammadi</surname><given-names>Mastaneh</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fakharzadeh</surname><given-names>Elham</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zamini</surname><given-names>Hediyeh</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zaer-Rezaee</surname><given-names>Hanieh</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jabbari</surname><given-names>Hossain</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref><xref ref-type="aff" rid="A02">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Merat</surname><given-names>Shahin</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A01"><sup>1</sup>Liver and Pancreatobiliary Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
</aff><aff id="A02"><sup>2</sup>Department of Infectious Diseases and Tropical Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
</aff><author-notes><corresp id="COR1"><label>*</label>Corresponding Author: Shahin Merat, MD Digestive Disease Research Institute, Shariati Hospital, N. Kargar St., Tehran 14117, Iran Tel: + 98 21 82415104 Fax:+ 98 21 82415400 <email>merat@tums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2014</year></pub-date><volume>6</volume><issue>1</issue><fpage>13</fpage><lpage>17</lpage><history><date date-type="received"><day>02</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>28</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2014 by Middle East Journal of Digestive Diseases</copyright-statement><copyright-year>2014</copyright-year><license><license-p>
This work is published by Middle East Journal of Digestive Diseases as an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>). Non-commercial uses of the work are permitted, provided the original work is properly cited.
</license-p></license></permissions><abstract><p>BACKGROUND</p><p>
Evidence indicates that insulin resistance results in poor sustained viral response (SVR) in patients with chronic
hepatitis C (CHC). Metformin is an oral hypoglycemic agent which improves insulin resistance.
</p><p>METHODS</p><p>
We sought to
determine if the addition of metformin to the treatment regimen could improve SVR in treatment-na&#x000ef;ve CHC patients
in a randomized, double-blind, placebo-controlled trial. We randomized 140 consecutive CHC patients to receive either
metformin 500 mg three times a day or placebo in addition to pegylated interferon (PEG-IFN) and ribavirin (RBV). Only
treatment-na&#x000ef;ve subjects aged between 15 and 65 years of age were included. SVR was defined as no detectable HCV RNA
six months after the end of treatment. Subjects who received at least one dose of PEG-IFN were included in the
finala nalysis.
</p><p>RESULTS</p><p>
The SVR rate in the metformin group was 75% versus 79% in controls (intention-to-treat) which
was not significantly different. Also, the difference between the placebo and metformin group was not significant in
subsets of different genotypes or those with homeostasis model assessment of insulin resistance (HOMA-IR) levels greater
than 2 or body mass index greater than 25. The most common complaint was gastrointestinal discomfort (13% in
metformin group versus 4% in controls; <italic>p</italic>=0.002) that lead to discontinuation of metformin in 8 participants.
</p><p>CONCLUSION</p><p>
Although triple therapy with metformin, PEG-IFN and RBV is relatively well tolerated, the addition of metformin did not
significantly improve viral response in CHC patients.
</p></abstract><kwd-group><kwd>Metformin</kwd><kwd>Hepatitis C</kwd><kwd>Insulin resistance</kwd></kwd-group><counts><table-count count="2"/><ref-count count="26"/><page-count count="5"/></counts></article-meta><notes><p>Please cite this paper as:</p><p>
Sharifi AH, Mohammadi M, Fakharzadeh E, Zamini H, Zaer-Rezaee H, Jabbari H, Merat S. Efficacy of Adding Metformin to Pegylated Interferon and Ribavirin in Treatment Na&#x000ef;ve Patients with Chronic Hepatitis C: A Randomized Double-Blind Controlled Trial. Middle East J Dig Dis 2013;6:13-7.
</p></notes></front><body><sec id="s1"><title>
INTRODUCTION
</title><p>
Insulin resistance and diabetes are major disease modifiers in chronic hepatitis C (CHC).<sup><xref rid="R01" ref-type="bibr">1</xref></sup> There is evidence for a role of insulin resistance, the best predictor of type 2 diabetes mellitus, in failure to achieve sustained viral response (SVR) in patients with CHC.<sup><xref rid="R01" ref-type="bibr">1</xref>-<xref rid="R03" ref-type="bibr">3</xref></sup> Also, insulin resistance has been associated with fibrosis progression, development of steatosis and greater risk of developing hepatocellular carcinoma in those infected with CHC.<sup><xref rid="R04" ref-type="bibr">4</xref>,<xref rid="R05" ref-type="bibr">5</xref></sup> In several prospective studies of CHC patients, higher fasting insulin levels and higher homeostasis model assessment of insulin resistance levels (HOMA-IR) were all independently associated with a poor viral response to therapy even in patients traditionally considered as those who responded very well to treatment.<sup><xref rid="R03" ref-type="bibr">3</xref></sup> Likewise it has been shown that patients who have previously failed anti-viral therapy have greater insulin resistance.<sup><xref rid="R02" ref-type="bibr">2</xref></sup>
</p><p>
Metformin is known to induce AMP-activated protein kinase (AMPK) through inhibition of AMP deaminase. AMPK is involved in both lipid and glucose metabolism. It also effectively inhibits viral replication.<sup><xref rid="R06" ref-type="bibr">6</xref></sup> It appears that infection of the hepatocyte with hepatitis C virus (HCV) leads to phosphorylation of AMPK resulting in reduced activity and thus enhanced viral replication as well as lipid accumulation.<sup><xref rid="R07" ref-type="bibr">7</xref></sup> Subsequently, it has been suggested that restoration of AMPK activity can inhibit viral replication. Metformin is known to induce AMPK through inhibition of AMP deaminase and this is the probable mechanism by which metformin, as well as other insulin sensitizing agents, may improve SVR in subjects with CHC.<sup><xref rid="R08" ref-type="bibr">8</xref>,<xref rid="R09" ref-type="bibr">9</xref></sup> There are a few studies which have investigated this idea but the results are far from convincing.<sup><xref rid="R10" ref-type="bibr">10</xref>-<xref rid="R14" ref-type="bibr">14</xref></sup>
</p><p>
There might also be other benefits for using insulin sensitizers in CHC such as a reduction in hepatocellular carcinoma or metabolic benefits from improvement in insulin resistance.<sup><xref rid="R05" ref-type="bibr">5</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup>
</p><p>
The present study is a double-blind randomized controlled trial designed to investigate the efficacy and safety of adding metformin to pegylated interferon (PEG-IFN) and ribavirin (RBV) in non-diabetic treatment-na&#x000ef;ve patients with CHC.
</p></sec><sec id="s2"><title>
MATERIALS AND METHODS
</title><sec id="s2-1"><title>
Subjects
</title><p>
The study was performed in the Shariati Hospital HCV clinic which is a tertiary referral center affiliated with Tehran University of Medical Sciences. We enrolled 140 consecutive treatment-na&#x000ef;ve patients with CHC who were considered eligible for treatment.
</p><p>
Entry criteria included male and female patients aged between 15 and 65 years who were HCV RNA positive and had evidence of HCV infection for at least 6 months. Exclusion criteria are summarized in
<xref ref-type="table" rid="T1">Table 1</xref>.
</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>
Exclusion criteria.
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Pregnant or willing to become pregnant in the next 18 months.</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Unable to use effective contraception during the next 18 months.</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Diabetes mellitus</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Contraindication for treatment with pegylated interferon (PEG-IFN), ribavirin (RBV) or metformin.</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Significant liver dysfunction (albumin &#x0003c;3 gr/dl, prothrombin time &#x0003e;15sec)</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Decompensated cirrhosis (Child-Pugh scores B or C)</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Concurrent hepatitis B or human immunodeficiency virus infection </td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Autoimmune hepatitis</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Primary biliary cirrhosis</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Sclerosing cholangitis</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Renal failure (creatinine &#x0003e;1.5 mg/dl for males and &#x0003e;1.4 mg/dl for females)</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Severe medical conditions (e.g., heart failure, hypoxic acidosis, psychosis, etc.)</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Refusal to provide consent for study participation.</td></tr></tbody></table></table-wrap></sec><sec id="s2-2"><title>
Clinical and laboratory assessments
</title><p>
We collected data on age, sex, weight, height, waist and hip circumference. The body mass index (BMI) was calculated as weight (kg) divided by the square of the height (meters).
</p><p>
After an overnight fasting of 12 hours, venous blood was drawn to determine hemoglobin, white blood cell count, platelet count, plasma glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), albumin, bilirubin, cholesterol (high- and low-density), insulin and C peptide.
</p><p>
A quantitative HCV-RNA polymerase chain reaction assay was used to determine baseline serum HCV-RNA levels (COBAS Amplicor HCV Monitor Test v 2.0, Roche Diagnostics, Mannheim, Germany). HCV genotypes were determined by melting curve analysis (MCA) using a single hybridization probe.
</p><p>
HOMA-IR was calculated by the following equation:
</p><p>
HOMA-IR = fasting plasma glucose (gr/dl) &#x000d7; fasting insulin level (mU/L)/405.
</p><p>
After obtaining verbal and written consents, all participants underwent percutaneous liver biopsies. The biopsies were scored according to Ishak et al.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> Steatosis was assessed as the percentage of hepatocytes that contained macrovesicular fat droplets and graded as no steatosis (&#x0003c;5%), mild (&#x0003c;33%), moderate (33%-66%) or severe (&#x0003e;66%).
</p></sec><sec id="s2-3"><title>
Treatment arms
</title><p>
All subjects received treatment at the time of enrollment in the study. Treatment included weekly injections of PEG-IFN (either 180 &#x003bc;g PEG-IFN alfa-2a or 1.5 &#x003bc;g/kg PEG-IFN alfa-2b) plus RBV 800, 1000, or 1200 mg per day depending on patient&#x02019;s weight and HCV genotype. Participants infected with genotypes 1 and 4 were treated for 48 weeks and those with genotypes 2 and 3 for 24 weeks. Furthermore, patients were randomized using a computer generated list to receive either 500 mg metformin three times daily or placebo for the treatment period (24 or 48 weeks depending on genotype). Both patients and researchers were blinded to the study medications.
</p></sec><sec id="s2-4"><title>
Endpoints
</title><p>
The primary endpoint of the study was no detectable HCV RNA in serum six months after the end of treatment (SVR, Cobas Amplicor TM HCV Monitor v 2.0, Roche Diagnostics, Mannheim, Germany).
</p></sec><sec id="s2-5"><title>
Ethics
</title><p>
The study protocol was approved by the Institutional Review Board and Ethics Committee of the Digestive Disease Research Institute of Tehran University of Medical Sciences and was registered in clinical trials.gov (ID: NCT00560690).
</p></sec></sec><sec id="s3"><title>
RESULTS
</title><p>
There were 140 participants enrolled in the study (70 participants per group). Of these, 135 subjects received at least one dose of PEG-IFN and were included in the analysis. The baseline characteristics of subjects are given in
<xref ref-type="table" rid="T2">Table 2</xref>.
</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>
Baseline characteristics of subjects.
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">
<bold>Variables</bold>
</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>Metformin</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Placebo</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Total</bold>
</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Sex (M/F)</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">60/8</td><td align="center" rowspan="1" colspan="1">57/10</td><td align="center" rowspan="1" colspan="1">117/18</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Age (mean&#x000b1;SD, yrs)</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">41.5&#x000b1;11.2</td><td align="center" rowspan="1" colspan="1">41.9&#x000b1;11.0</td><td align="center" rowspan="1" colspan="1">41.7&#x000b1;11.1</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="2" colspan="1">Genotype</td><td align="center" rowspan="1" colspan="1">1 and 4</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">67</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td align="center" rowspan="1" colspan="1">2 and 3</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1"/></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">
HOMA-IR<break/> (mean&#x000b1;SD)
</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.88&#x000b1;1.50</td><td align="center" rowspan="1" colspan="1">2.14&#x000b1;1.81</td><td align="center" rowspan="1" colspan="1">2.00&#x000b1;1.66</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">BMI (mean&#x000b1;SD, kg/m/m)</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">24.2&#x000b1;3.9</td><td align="center" rowspan="1" colspan="1">24.8&#x000b1;3.1</td><td align="center" rowspan="1" colspan="1">24.5&#x000b1;3.6</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">Viral load (IU/ml)</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4,186,000</td><td align="center" rowspan="1" colspan="1">2,732,000</td><td align="center" rowspan="1" colspan="1">3,459,000</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">
Histologic grade<break/> (mean&#x000b1;SD)
</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.2&#x000b1;2.8</td><td align="center" rowspan="1" colspan="1">5.8&#x000b1;2.5</td><td align="center" rowspan="1" colspan="1">6.0&#x000b1;2.7</td></tr><tr style="border-width: 1px 0px 0pt 0px ; border-style:solid none none none;border-color:#00adee"><td rowspan="1" colspan="1">
Histologic stage<break/> (mean&#x000b1;SD)
</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.8&#x000b1;1.6</td><td align="center" rowspan="1" colspan="1">1.5&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">1.6&#x000b1;1.4</td></tr></tbody></table></table-wrap><p>
There were 16 participants lost to follow-up (8 from each group). The SVR rate in the metformin group was 75% versus 79% in controls (intention-to-treat) which was not significantly different. The difference between the SVR of the two groups was not significant in the per-protocol analysis in subjects who completed the full course of treatment with PEG-IFN, RBV and metformin (or placebo). A subset of participants with insulin resistance (HOMA-IR &#x0003e;2) and a subset with BMI &#x0003e;25kg/m<sup>2</sup> were also analyzed. There was no significant difference in SVR between the placebo (<italic>p</italic>=0.20) and metformin (<italic>p</italic>=0.19) groups. The SVR for genotypes 1 and 4 subjects was 71.6% and for genotypes 2 and 3, 82.4%. The difference between the placebo and metformin groups was again non-significant when separately calculated for each genotype (<italic>p</italic>=0.26 for genotypes 1 and 4 and <italic>p</italic>=0.86 for genotypes 2 and 3).
</p><p>
The most common adverse event observed during treatment was gastrointestinal discomfort seen in 13% of metformin group patients and 4% of controls (<italic>p</italic>=0.002).These adverse events lead to discontinuation of metformin in 8 subjects.
</p></sec><sec id="s4"><title>
DISCUSSION
</title><p>
It is well established that infection with HCV can induce insulin resistance and fat accumulation in the liver and multiple molecular mechanisms have been described for this phenomenon.<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> There is further evidence that this insulin resistance provides some sort of survival advantage for the virus.<sup><xref rid="R01" ref-type="bibr">1</xref>,<xref rid="R03" ref-type="bibr">3</xref>,<xref rid="R07" ref-type="bibr">7</xref>,<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> Such studies form the rationale for trials of insulin sensitizers in CHC with the assumption that reversing insulin resistance may deprive the virus of this advantage and hinder its replication.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup>
</p><p>
A few researchers have investigated metformin in CHC. Romero-Gomez et al. in a design very similar to ours randomized 123 consecutive patients with CHC genotype 1 to receive metformin versus placebo in addition to PEG-IFN and RBV. They failed to observe a significant benefit for metformin although a slight benefit was observed for female subjects.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> The number of females with genotype 1 infection was too small in our study to allow any meaningful conclusion.
</p><p>
In a more recent study by Yu et al. 98 patients with genotype 1 were studied in a similar design and a significant advantage was observed for the metformin group although the p-value was borderline at 0.043.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> In our study we did not observe a significant difference in genotype 1 subjects.
</p><p>
We also analyzed a subgroup of our patients with initially high HOMA-IR to see if metformin was more effective in this group but again failed to demonstrate any advantage. Neither did we find a benefit among overweight and obese subjects (BMI&#x0003e;25).
</p><p>
There are other proposed mechanisms for insulin resistance in CHC, one of which is through decreased activity of peroxisome proliferator activated receptor gamma(PPAR&#x003b3;).<sup><xref rid="R23" ref-type="bibr">23</xref></sup> Pioglitazone, a PPAR&#x003b3; agonist, has been studied in subjects with CHC with varying degrees of success but overall the results have been disappointing.<sup><xref rid="R24" ref-type="bibr">24</xref>-<xref rid="R26" ref-type="bibr">26</xref></sup>
</p><p>
By reviewing the literature it appears that any improvements in SVR by insulin sensitizers such as metformin are likely to be small.
</p><p>
We did not observe any benefit in adding metformin to the treatment of CHC in terms of improving SVR. Further research with larger number of patients will clarify this issue. However due to the recent approval of direct acting antivirals with very high SVR rates we doubt that such studies are justified.
</p></sec><sec id="s5"><title>
CONFLICT OF INTEREST
</title><p>
The authors declare no conflict of interest related to this work.
</p></sec></body><back><ref-list><title>References</title><ref id="R01"><label>1</label><element-citation publication-type="journal"><name><surname>El-Zayadi</surname><given-names>AR</given-names></name><name><surname>Anis</surname><given-names>M</given-names></name><article-title>Hepatitis C virus induced insulin resistance impairs response to anti viral therapy</article-title><source>World J Gastroenterol</source><year>2012</year><volume>18</volume><fpage>212</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">22294824</pub-id></element-citation></ref><ref id="R02"><label>2</label><element-citation publication-type="journal"><name><surname>Poustchi</surname><given-names>H</given-names></name><name><surname>Negro</surname><given-names>F</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Cua</surname><given-names>IH</given-names></name><name><surname>Brandt</surname><given-names>LR</given-names></name><name><surname>Kench</surname><given-names>JG</given-names></name><etal/><article-title>Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3</article-title><source>J Hepatol</source><year>2008</year><volume>48</volume><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">17977612</pub-id></element-citation></ref><ref id="R03"><label>3</label><element-citation publication-type="journal"><name><surname>Elgouhari</surname><given-names>HM</given-names></name><name><surname>Zein</surname><given-names>CO</given-names></name><name><surname>Hanouneh</surname><given-names>I</given-names></name><name><surname>Feldstein</surname><given-names>AE</given-names></name><name><surname>Zein</surname><given-names>NN</given-names></name><article-title>Diabetes Mellitus Is Associated with Impaired Response to Antiviral Therapy in Chronic Hepatitis C Infection</article-title><source>Dig Dis Sci</source><year>2009</year><volume>54</volume><fpage>2699</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">19148751</pub-id></element-citation></ref><ref id="R04"><label>4</label><element-citation publication-type="journal"><name><surname>Popov</surname><given-names>VB</given-names></name><name><surname>Lim</surname><given-names>JK</given-names></name><article-title>Impact of insulin-sensitizing agents on risk for liver cancer and liver-related death in diabetic patients with compensated hepatitis C cirrhosis</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><fpage>2398</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">21816800</pub-id></element-citation></ref><ref id="R05"><label>5</label><element-citation publication-type="journal"><name><surname>Nkontchou</surname><given-names>G</given-names></name><name><surname>Cosson</surname><given-names>E</given-names></name><name><surname>Aout</surname><given-names>M</given-names></name><name><surname>Mahmoudi</surname><given-names>A</given-names></name><name><surname>Bourcier</surname><given-names>V</given-names></name><name><surname>Charif</surname><given-names>I</given-names></name><etal/><article-title>Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><fpage>2601</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21752887</pub-id></element-citation></ref><ref id="R06"><label>6</label><element-citation publication-type="journal"><name><surname>Hardie</surname><given-names>DG</given-names></name><article-title>Adenosine monophosphate-activated protein kinase: a central regulator of metabolism with roles in diabetes, cancer, and viral infection</article-title><source>Cold Spring Harb Symp Quant Biol</source><year>2011</year><volume>76</volume><fpage>155</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">22071265</pub-id></element-citation></ref><ref id="R07"><label>7</label><element-citation publication-type="journal"><name><surname>Mankouri</surname><given-names>J</given-names></name><name><surname>Tedbury</surname><given-names>PR</given-names></name><name><surname>Gretton</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>ME</given-names></name><name><surname>Griffin</surname><given-names>SD</given-names></name><name><surname>Dallas</surname><given-names>ML</given-names></name><etal/><article-title>Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>11549</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">20534540</pub-id></element-citation></ref><ref id="R08"><label>8</label><element-citation publication-type="journal"><name><surname>Ouyang</surname><given-names>J</given-names></name><name><surname>Parakhia</surname><given-names>RA</given-names></name><name><surname>Ochs</surname><given-names>RS</given-names></name><article-title>Metformin activates AMP kinase through inhibition of AMP deaminase</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">21059655</pub-id></element-citation></ref><ref id="R09"><label>9</label><element-citation publication-type="journal"><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Fenyk-Melody</surname><given-names>J</given-names></name><etal/><article-title>Role of AMP-activated protein kinase in mechanism of metformin action</article-title><source>J Clin Invest</source><year>2001</year><volume>108</volume><fpage>1167</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">11602624</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>Harris</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><article-title>Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C</article-title><source>Ann Pharmacother</source><year>2013</year><volume>47</volume><fpage>1348</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">24259699</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Yu</surname><given-names>JW</given-names></name><name><surname>Sun</surname><given-names>LJ</given-names></name><name><surname>Zhao</surname><given-names>YH</given-names></name><name><surname>Kang</surname><given-names>P</given-names></name><name><surname>Yan</surname><given-names>BZ</given-names></name><article-title>The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance</article-title><source>Int J Infect Dis</source><year>2012</year><volume>16</volume><fpage>e436</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">22486858</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Kawaguchi</surname><given-names>T</given-names></name><name><surname>Sata</surname><given-names>M</given-names></name><article-title>Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>1943</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">20419831</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Conjeevaram HS</surname><given-names>ea</given-names></name><article-title>A Randomized, Double-Blind, Placebo-Controlled Study of PPAR-gamma Agonist Pioglitazone Given in Combination with Peginterferon and Ribavirin in Patients with Genotype-1 Chronic Hepatitis C</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><fpage>Abstract 168</fpage></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><name><surname>Romero-Gomez</surname><given-names>M</given-names></name><name><surname>Diago</surname><given-names>M</given-names></name><name><surname>Andrade</surname><given-names>RJ</given-names></name><name><surname>Calleja</surname><given-names>JL</given-names></name><name><surname>Salmeron</surname><given-names>J</given-names></name><name><surname>Fernandez-Rodriguez</surname><given-names>CM</given-names></name><etal/><article-title>Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin</article-title><source>Hepatology</source><year>2009</year><volume>50</volume><fpage>1702</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19845037</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Pollak</surname><given-names>M</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><article-title>Metformin and hepatic carcinogenesis</article-title><source>Cancer Prev Res (Phila)</source><year>2012</year><volume>5</volume><fpage>500</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">22467079</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Kiran</surname><given-names>Z</given-names></name><name><surname>Zuberi</surname><given-names>BF</given-names></name><name><surname>Anis</surname><given-names>D</given-names></name><name><surname>Qadeer</surname><given-names>R</given-names></name><name><surname>Hassan</surname><given-names>K</given-names></name><name><surname>Afsar</surname><given-names>S</given-names></name><article-title>Insulin resistance in non-diabetic patients of chronic Hepatitis C</article-title><source>Pak J Med Sci</source><year>2013</year><volume>29</volume><fpage>201</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">24353540</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Ishak</surname><given-names>K</given-names></name><name><surname>Baptista</surname><given-names>A</given-names></name><name><surname>Bianchi</surname><given-names>L</given-names></name><name><surname>Callea</surname><given-names>F</given-names></name><name><surname>De Groote</surname><given-names>J</given-names></name><name><surname>Gudat</surname><given-names>F</given-names></name><etal/><article-title>Histological grading and staging of chronic hepatitis</article-title><source>J Hepatol</source><year>1995</year><volume>22</volume><fpage>696</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7560864</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Caronia</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><name><surname>Pagliaro</surname><given-names>L</given-names></name><name><surname>Carr</surname><given-names>C</given-names></name><name><surname>Palazzo</surname><given-names>U</given-names></name><name><surname>Petrik</surname><given-names>J</given-names></name><etal/><article-title>Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection</article-title><source>Hepatology</source><year>1999</year><volume>30</volume><fpage>1059</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">10498660</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><name><surname>Douglas</surname><given-names>MW</given-names></name><name><surname>George</surname><given-names>J</given-names></name><article-title>Molecular mechanisms of insulin resistance in chronic hepatitis C</article-title><source>World J Gastroenterol</source><year>2009</year><volume>15</volume><fpage>4356</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">19764085</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><name><surname>D&#x02019;Souza</surname><given-names>R</given-names></name><name><surname>Sabin</surname><given-names>CA</given-names></name><name><surname>Foster</surname><given-names>GR</given-names></name><article-title>Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy</article-title><source>Am J Gastroenterol</source><year>2005</year><volume>100</volume><fpage>1509</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">15984973</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><name><surname>Romero-Gomez</surname><given-names>M</given-names></name><name><surname>Del Mar Viloria</surname><given-names>M</given-names></name><name><surname>Andrade</surname><given-names>RJ</given-names></name><name><surname>Salmeron</surname><given-names>J</given-names></name><name><surname>Diago</surname><given-names>M</given-names></name><name><surname>Fernandez-Rodriguez</surname><given-names>CM</given-names></name><etal/><article-title>Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients</article-title><source>Gastroenterology</source><year>2005</year><volume>128</volume><fpage>636</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">15765399</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><name><surname>Leandro</surname><given-names>G</given-names></name><name><surname>Mangia</surname><given-names>A</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Fabris</surname><given-names>P</given-names></name><name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name><name><surname>Colloredo</surname><given-names>G</given-names></name><etal/><article-title>Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>1636</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">16697727</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><name><surname>Eslam</surname><given-names>M</given-names></name><name><surname>Khattab</surname><given-names>MA</given-names></name><name><surname>Harrison</surname><given-names>SA</given-names></name><article-title>Peroxisome proliferator-activated receptors and hepatitis C virus</article-title><source>Therap Adv Gastroenterol</source><year>2011</year><volume>4</volume><fpage>419</fpage><lpage>31</lpage></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><name><surname>Overbeck</surname><given-names>K</given-names></name><name><surname>Genne</surname><given-names>D</given-names></name><name><surname>Golay</surname><given-names>A</given-names></name><name><surname>Negro</surname><given-names>F</given-names></name><article-title>Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin</article-title><source>J Hepatol</source><year>2008</year><volume>49</volume><fpage>295</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18555553</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><name><surname>Harrison</surname><given-names>SA</given-names></name><name><surname>Hamzeh</surname><given-names>FM</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Pandya</surname><given-names>PK</given-names></name><name><surname>Sheikh</surname><given-names>MY</given-names></name><name><surname>Vierling</surname><given-names>JM</given-names></name><article-title>Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin</article-title><source>Hepatology</source><year>2012</year><volume>56</volume><fpage>464</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">22334369</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><name><surname>Chojkier</surname><given-names>M</given-names></name><name><surname>Elkhayat</surname><given-names>H</given-names></name><name><surname>Sabry</surname><given-names>D</given-names></name><name><surname>Donohue</surname><given-names>M</given-names></name><name><surname>Buck</surname><given-names>M</given-names></name><article-title>Pioglitazone decreases hepatitis C viral load in overweight, treatment naive, genotype 4 infected-patients: a pilot study</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e31516</fpage><pub-id pub-id-type="pmid">22412837</pub-id></element-citation></ref></ref-list></back></article>